Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dodwell

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival studyBrian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, et al.
Frontiers in Pharmacology|September 5, 2025
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapiesSteven Simoens, David Dodwell, Michael Hartevelt, et al.
The Lancet. Oncology|July 19, 2014
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trialRobert Coleman, David Cameron, David Dodwell, et al.
Breast (Edinburgh, Scotland)|April 17, 2020
Radiological audit of interval breast cancers: Estimation of tumour growth ratesEmma G MacInnes, Stephen W Duffy, Julie A Simpson, et al.
The British Journal of Radiology|June 9, 2021
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological responseWilliam Stevens, Isabelle M Farrow, Leonidas Georgiou, et al.
Frontiers in Pharmacology|September 22, 2025
Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapiesSteven Simoens, David Dodwell, Michael Hartevelt, et al.
The Lancet. Oncology|February 19, 2013
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)Bernhard C Pestalozzi, Eileen Holmes, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2017
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized TrialsCarolyn Taylor, Candace Correa, Frances K Duane, et al.
Breast (Edinburgh, Scotland)|January 9, 2022
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 studyAnthony J Maxwell, Bridget Hilton, Karen Clements, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival studyBrian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, et al.
Frontiers in Pharmacology|September 5, 2025
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapiesSteven Simoens, David Dodwell, Michael Hartevelt, et al.
The Lancet. Oncology|July 19, 2014
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trialRobert Coleman, David Cameron, David Dodwell, et al.
Breast (Edinburgh, Scotland)|April 17, 2020
Radiological audit of interval breast cancers: Estimation of tumour growth ratesEmma G MacInnes, Stephen W Duffy, Julie A Simpson, et al.
The British Journal of Radiology|June 9, 2021
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological responseWilliam Stevens, Isabelle M Farrow, Leonidas Georgiou, et al.
Frontiers in Pharmacology|September 22, 2025
Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapiesSteven Simoens, David Dodwell, Michael Hartevelt, et al.
The Lancet. Oncology|February 19, 2013
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)Bernhard C Pestalozzi, Eileen Holmes, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2017
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized TrialsCarolyn Taylor, Candace Correa, Frances K Duane, et al.
Breast (Edinburgh, Scotland)|January 9, 2022
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 studyAnthony J Maxwell, Bridget Hilton, Karen Clements, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Pageof 12